Jcem1279.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Jcem1279.Pdf JCEM ONLINE Brief Report—Endocrine Research Germline Mutations of the TMEM127 Gene in Patients with Paraganglioma of Head and Neck and Extraadrenal Abdominal Sites Hartmut P. H. Neumann, Maren Sullivan, Aurelia Winter, Angelica Malinoc, Michael M. Hoffmann, Carsten C. Boedeker, Hartmut Bertz, Martin K. Walz, Lars C. Moeller, Kurt W. Schmid, and Charis Eng Downloaded from https://academic.oup.com/jcem/article/96/8/E1279/2833767 by guest on 27 September 2021 Department of Nephrology and General Medicine (H.P.H.N., M.S., A.W., A.M.) and Divisions of Clinical Chemistry (M.M.H.), Otolaryngology (C.C.B.), and Hematology and Oncology (H.B.), University Medical Center, Albert-Ludwigs-University, D-79106 Freiburg, Germany; Department of Visceral Surgery (M.K.W.), Kliniken Essen Mitte, D-45276 Essen, Germany; Departments of Endocrinology (L.C.M.) and Pathology (K.W.S.), University of Duisburg-Essen, D-45141 Essen, Germany; and Genomic Medicine Institute (C.E.), Lerner Research Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195 Background: Hereditary pheochromocytoma is associated with germline mutations of a set of susceptibility genes to which the TMEM127 gene has recently been added. Patients with TMEM127 mutations have been thus far exclusively identified with adrenal tumors. Patients and Methods: A population-based series of 48 consecutive individuals from the European- American Pheochromocytoma Paraganglioma Registry with multiple paraganglial tumors and, of these, one extraadrenal paraganglial tumor were selected for this study. They all had normal results when screened for germline mutations of the genes RET, VHL, SDHB, SDHC, and SDHD. Germline mutation analysis of the TMEM127 gene included a search for intragenic mutations and large rearrangements. Results: Of the 48 eligible patients with extraadrenal paraganglial tumors, two (4.2%) were found to have TMEM127 mutations. One patient had multiple head and neck paraganglioma and one retroperitoneal extraadrenal and adrenal tumor. Conclusion: TMEM127 germline mutations confer risks of extraadrenal paraganglial tumors in addi- tion to the documented adrenal pheochromocytoma. Thus, surveillance for extraadrenal and adrenal paraganglial tumors is likely warranted in TMEM127 mutation carriers, although the true prevalence should be evaluated in patients with extraadrenal paraganglial tumors. (J Clin Endocrinol Metab 96: E1279–E1282, 2011) he family of susceptibility genes for hereditary pheo- sia syndromes are, in historical order, neurofibromato- T chromocytomas and paragangliomas is growing sis type 1, multiple endocrine neoplasia type 2, von Hip- and has implications for generalists and multiple spe- pel-Lindau disease, paraganglioma syndrome types 1, 2, cialties because of their protean location, symptomatol- 3, and 4, and furthermore, a distinct disorder exclusively ogy, and presentation. Patients with hereditary pheo- associated with adrenal pheochromocytoma (1). The re- chromocytoma or paraganglioma may either have a spective susceptibility genes are NF1, RET, VHL, SDHD, complex neoplasia syndrome or have tumors of the sdh5/SDHAF2, SDHC, SDHB, and TMEM127 (2–4). Be- paraganglial system as the only condition. The neopla- cause of clinical outcome studies of these genes, except for ISSN Print 0021-972X ISSN Online 1945-7197 Printed in U.S.A. Copyright © 2011 by The Endocrine Society doi: 10.1210/jc.2011-0114 Received January 13, 2011. Accepted April 26, 2011. First Published Online May 25, 2011 J Clin Endocrinol Metab, August 2011, 96(8):E1279–E1282 jcem.endojournals.org E1279 E1280 Neumann et al. TMEM127 Mutations in Paragangliomas J Clin Endocrinol Metab, August 2011, 96(8):E1279–E1282 the most recent SDHAF2 and TMEM127, specific gene- Board-approved questionnaire for enrollment as experimental informed clinical surveillance can be performed. The most controls. recently identified gene is TMEM127 (4). The phenotype DNA variants of missense type were regarded as pathogenic mutations, if they do not occur in the controls. In addition, of mutation carriers has recently been described by Yao et pathogenicity was supported by in silico analysis tools Mutation al. (1). Of 990 probands, 20 (2%) patients have been iden- Taster (6), PolyPhen (7), and SNAP (8), which predict possible tified with germline TMEM127 mutations. All mutation impact of single amino acid substitutions on protein structure carriers in that study were found to exclusively carry ad- and function. renal paraganglial tumors, i.e. pheochromocytomas. Ex- traadrenal paraganglial tumors were not reported. If this held true, then finding a TMEM127 mutation would sug- Results gest only adrenal surveillance. Here, we sought to deter- Downloaded from https://academic.oup.com/jcem/article/96/8/E1279/2833767 by guest on 27 September 2021 We analyzed for intragenic germline mutations of the mine whether extraadrenal paraganglial tumors were a TMEM127 gene in 48 unrelated registrants selected for part of the phenotypic spectrum of germline TMEM127 two or more paraganglial tumors, of which at least one mutation carriers. must have been outside the adrenal glands. Of the 48 pa- tients, 24 had tumors of the head and neck. Of these 24, 22 had head and neck tumors only, whereas one patient Subjects and Methods also had a thoracic and a retroperitoneal extraadrenal tu- Research participants mor, and one patient had bilateral adrenal tumors. Of the The research participants were a nested series from the pop- remaining 24 patients, all had retroperitoneal extraadre- ulation-based European-American Pheochromocytoma-Para- nal tumors, with four exclusively in this location. In ad- ganglioma Registry (5). All registrations are based on a uniform dition, 20 of these 24 also had tumors in the adrenals, and questionnaire that includes capture of demographic data such as among the 20 with adrenal involvement, six had bilateral age, gender, and place of residence as well as clinical data such disease and the remaining 14, unilateral. Of the six pa- as biochemical data regarding catecholamines and metaneph- tients with bilateral adrenal disease, two also had thoracic rines, imaging data from magnetic resonance or computerized tomography and scintigraphic procedures as well as number and involvement. Pelvic tumors did not occur. Age at diagnosis location of the tumors and their biological behavior as benign or was 11–75 (median 40) years, and male to female ratio malignant disease. Criteria for malignancy were lymph node or was 1:2.5. A family history of paraganglial tumors was distant (extraparaganglial) metastases. present in three of the 48 patients. Of the 48 patients, 35 For purposes of this study, only unrelated symptomatic pa- are German, four Polish, three French, two each Swiss and tients, who were mutation and deletion negative for RET, VHL, Greek, and one each Spanish and Finnish. SDHB, SDHC, SDHD, and NF1, were included. Other inclusion criteria include having at least two paraganglial tumors, at least Among the 48 eligible patients, two patients (4.2%) one of which must be an extraadrenal paraganglial tumor. An were found to have germline TMEM127 mutations, both important exclusion criterion was that none of these research of missense type (Table 1). These two patients were mu- participants should also be included in the cohort described by tation negative for SDHAF2/SDHA. None of the 100 con- Yao et al. (1). A nested series of 48 unrelated individuals within trols showed these two missense mutations, and in silico the registry met eligibility criteria. This sample size is powered (P Ͼ 0.8) to detect even a 6% prevalence of TMEM127 muta- tion-positive cases. All subjects signed informed consent in accordance with our TABLE 1. Demographic and clinical information for the respective institutions’ Human Subjects Protection Committee/ TMEM127 mutation-positive individuals Ethical Committee. Variable Case I Case II Mutation analysis of TMEM127 Age at diagnosis (yr) 34 51 Gender Female Female Genomic DNA was extracted from EDTA-anticoagulated pe- Tumor number 2 6 ripheral white blood cells from each subject using standard pro- Tumor location CBT, CBT 4 adrenal left cedures. The gene TMEM127 was analyzed for intragenic mu- 1 adrenal right tations and large deletions and rearrangements. Mutation 1 extraadrenal screening was performed by denaturing HPLC (WAVE system, retroperitoneal model 3500 HT; Transgenomic, Glasgow, UK) followed by se- Malignant No No quencing (ABI 3130) for patients who showed abnormal dena- Family history Negative Negative turing HPLC chromatograms. Deletion/rearrangement analysis Other neoplasias Acute myeloid was performed using multiplex ligation-dependent probe am- leukemia TMEM127 mutation c.325 T3 c.553 G3 plification. Genomic DNA was extracted from 100 ancestry- C (p.S109P) A (p.G185R) matched population-based controls who were healthy anony- mous blood donors or who filled in an Institutional Review CBT, Carotid body tumor. J Clin Endocrinol Metab, August 2011, 96(8):E1279–E1282 jcem.endojournals.org E1281 analyses support the pathogenicity of these mutations. In if indeed TMEM127 mutations confer only risk for adre- addition, we observed the DNA variant TMEM127 c.621 nal pheochromocytomas, then surveillance can be lim- G3A (p.A207A) in 29% of the probands and 8% of the ited to the adrenals. However, in our study of a popu- controls. lation-based series with extraadrenal paraganglial The two mutation-positive females were aged 34 and tumors, we identified two unrelated individuals
Recommended publications
  • Genomic and Transcriptomic Alterations Associated with Drug Vulnerabilities and Prognosis in Adenocarcinoma at the Gastroesophageal Junction
    ARTICLE https://doi.org/10.1038/s41467-020-19949-6 OPEN Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction Yuan Lin1,8, Yingying Luo 2,8, Yanxia Sun 2,8, Wenjia Guo 2,3,8, Xuan Zhao2,8, Yiyi Xi2, Yuling Ma 2, ✉ ✉ Mingming Shao2, Wen Tan2, Ge Gao 1,4 , Chen Wu 2,5,6 & Dongxin Lin2,5,7 1234567890():,; Adenocarcinoma at the gastroesophageal junction (ACGEJ) has dismal clinical outcomes, and there are currently few specific effective therapies because of limited knowledge on its genomic and transcriptomic alterations. The present study investigates genomic and tran- scriptomic changes in ACGEJ from Chinese patients and analyzes their drug vulnerabilities and associations with the survival time. Here we show that the major genomic changes of Chinese ACGEJ patients are chromosome instability promoted tumorigenic focal copy- number variations and COSMIC Signature 17-featured single nucleotide variations. We provide a comprehensive profile of genetic changes that are potentially vulnerable to existing therapeutic agents and identify Signature 17-correlated IFN-α response pathway as a prog- nostic marker that might have practical value for clinical prognosis of ACGEJ. These findings further our understanding on the molecular biology of ACGEJ and may help develop more effective therapeutic strategies. 1 Beijing Advanced Innovation Center for Genomics (ICG), Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China. 2 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3 Cancer Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
    [Show full text]
  • Paraganglioma (PGL) Tumors in Patients with Succinate Dehydrogenase-Related PCC–PGL Syndromes: a Clinicopathological and Molecular Analysis
    T G Papathomas and others Non-PCC/PGL tumors in the SDH 170:1 1–12 Clinical Study deficiency Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC–PGL syndromes: a clinicopathological and molecular analysis Thomas G Papathomas1, Jose Gaal1, Eleonora P M Corssmit2, Lindsey Oudijk1, Esther Korpershoek1, Ketil Heimdal3, Jean-Pierre Bayley4, Hans Morreau5, Marieke van Dooren6, Konstantinos Papaspyrou7, Thomas Schreiner8, Torsten Hansen9, Per Arne Andresen10, David F Restuccia1, Ingrid van Kessel6, Geert J L H van Leenders1, Johan M Kros1, Leendert H J Looijenga1, Leo J Hofland11, Wolf Mann7, Francien H van Nederveen12, Ozgur Mete13,14, Sylvia L Asa13,14, Ronald R de Krijger1,15 and Winand N M Dinjens1 1Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands, 2Department of Endocrinology, Leiden University Medical Center, Leiden,The Netherlands, 3Section for Clinical Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, 4Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, 5Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 6Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, 7Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, 8Section for Specialized Endocrinology,
    [Show full text]
  • Download Via Github on RNA-Seq and Chip-Seq Data Analysis and the University of And/Or Bioconductor [33–35, 38–40]
    Kumka and Bauer BMC Genomics (2015) 16:895 DOI 10.1186/s12864-015-2162-4 RESEARCH ARTICLE Open Access Analysis of the FnrL regulon in Rhodobacter capsulatus reveals limited regulon overlap with orthologues from Rhodobacter sphaeroides and Escherichia coli Joseph E. Kumka and Carl E. Bauer* Abstract Background: FNR homologues constitute an important class of transcription factors that control a wide range of anaerobic physiological functions in a number of bacterial species. Since FNR homologues are some of the most pervasive transcription factors, an understanding of their involvement in regulating anaerobic gene expression in different species sheds light on evolutionary similarity and differences. To address this question, we used a combination of high throughput RNA-Seq and ChIP-Seq analysis to define the extent of the FnrL regulon in Rhodobacter capsulatus and related our results to that of FnrL in Rhodobacter sphaeroides and FNR in Escherichia coli. Results: Our RNA-seq results show that FnrL affects the expression of 807 genes, which accounts for over 20 % of the Rba. capsulatus genome. ChIP-seq results indicate that 42 of these genes are directly regulated by FnrL. Importantly, this includes genes involved in the synthesis of the anoxygenic photosystem. Similarly, FnrL in Rba. sphaeroides affects 24 % of its genome, however, only 171 genes are differentially expressed in common between two Rhodobacter species, suggesting significant divergence in regulation. Conclusions: We show that FnrL in Rba. capsulatus activates photosynthesis while in Rba. sphaeroides FnrL regulation reported to involve repression of the photosystem. This analysis highlights important differences in transcriptional control of photosynthetic events and other metabolic processes controlled by FnrL orthologues in closely related Rhodobacter species.
    [Show full text]
  • About SDHD Gene Mutations
    About SDHD Gene Mutations About Genes Recommendations Genes are in every cell in our bodies. Genes are made Knowing if you have an SDHD mutation can help you of DNA, which gives instructions to cells about how to grow manage your medical care. and work together. We have two copies of each gene in each cell—one from our mother and one from our father. When MEN AND WOMEN genes work right, they help stop cancer cells from developing. If you know you have an SDHD mutation, it is important If one copy of a gene has a mutation, it cannot function as it to find tumors early. It is also important to tell your doctor should. This increases the risk for certain cancers. that you have this mutation before any medical procedures. TheSDH genes have instructions for turning food into energy Recommendations may vary according to your age. and helping fix mistakes in DNA. The four genes involved are Ages 8-18: SDHA, SDHB, SDHC, and SDHD. If there is a mutation in one • MRI of the whole body every 2-3 years of these genes, it can cause cells to grow and divide too much. This • Neck MRI every 2-3 years can lead to tumors called paragangliomas and pheochromocytomas. These tumors are often benign (non-cancerous) but can be Adults: cancer and spread in some cases. This condition is called • PET/CT scan as your doctor recommends hereditary paraganglioma/pheochromocytoma syndrome. All ages: Paragangliomas and Pheochromocytomas • Physical exam every year with blood pressure check Paragangliomas (PGLs) are slow-growing tumors that develop • Blood test every year along nerves or blood vessels.
    [Show full text]
  • Multiple Endocrine Neoplasia Type 2: an Overview Jessica Moline, MS1, and Charis Eng, MD, Phd1,2,3,4
    GENETEST REVIEW Genetics in Medicine Multiple endocrine neoplasia type 2: An overview Jessica Moline, MS1, and Charis Eng, MD, PhD1,2,3,4 TABLE OF CONTENTS Clinical Description of MEN 2 .......................................................................755 Surveillance...................................................................................................760 Multiple endocrine neoplasia type 2A (OMIM# 171400) ....................756 Medullary thyroid carcinoma ................................................................760 Familial medullary thyroid carcinoma (OMIM# 155240).....................756 Pheochromocytoma ................................................................................760 Multiple endocrine neoplasia type 2B (OMIM# 162300) ....................756 Parathyroid adenoma or hyperplasia ...................................................761 Diagnosis and testing......................................................................................756 Hypoparathyroidism................................................................................761 Clinical diagnosis: MEN 2A........................................................................756 Agents/circumstances to avoid .................................................................761 Clinical diagnosis: FMTC ............................................................................756 Testing of relatives at risk...........................................................................761 Clinical diagnosis: MEN 2B ........................................................................756
    [Show full text]
  • Generated by SRI International Pathway Tools Version 25.0, Authors S
    Authors: Pallavi Subhraveti Peter D Karp Ingrid Keseler An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Anamika Kothari Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000442315Cyc: Rubellimicrobium thermophilum DSM 16684 Cellular Overview Connections between pathways are omitted for legibility. Ron Caspi lipid II (meso phosphate diaminopimelate sn-glycerol containing) phosphate dCTP 3-phosphate predicted ABC RS07495 RS12165 RS03605 transporter RS13105 of phosphate lipid II (meso dCTP sn-glycerol diaminopimelate phosphate 3-phosphate containing) phosphate Secondary Metabolite Degradation Storage Compound Biosynthesis Tetrapyrrole Biosynthesis Hormone Biosynthesis Aromatic Compound Aldehyde Degradation UDP-N-acetyl- Biosynthesis undecaprenyl- a mature (4R)-4-hydroxy- an L-glutamyl- a [protein]-L- queuosine at Macromolecule Modification myo-inositol degradation I α-D-glucosamine adenosylcobinamide a purine L-canavanine 5'-deoxyadenosine sec Metabolic Regulator Biosynthesis Amine and Polyamine Biosynthesis polyhydroxybutanoate biosynthesis siroheme biosynthesis methylglyoxal degradation I diphospho-N- peptidoglycan 2-oxoglutarate Gln β-isoaspartate glu position 34 ser a tRNA indole-3-acetate
    [Show full text]
  • First-Positive Surveillance Screening in an Asymptomatic SDHA Germline Mutation Carrier
    ID: 19-0005 -19-0005 G White and others SDHA surveillance screen ID: 19-0005; May 2019 detected PGL DOI: 10.1530/EDM-19-0005 First-positive surveillance screening in an asymptomatic SDHA germline mutation carrier Correspondence should be addressed Gemma White, Nicola Tufton and Scott A Akker to S A Akker Email Department of Endocrinology, St. Bartholomew’s Hospital, Barts Health NHS Trust, London, UK [email protected] Summary At least 40% of phaeochromocytomas and paraganglioma’s (PPGLs) are associated with an underlying genetic mutation. The understanding of the genetic landscape of these tumours has rapidly evolved, with 18 associated genes now identified.Amongthese,mutationsinthesubunitsofsuccinatedehydrogenasecomplex(SDH) are the most common, causing around half of familial PPGL cases. Occurrence of PPGLs in carriers of SDHB, SDHC and SDHD subunit mutations has been long reported, but it is only recently that variants in the SDHA subunit have been linked to PPGL formation. Previously documented cases have, to our knowledge, only been found in isolated cases where pathogenic SDHA variants wereidentifiedretrospectively.Wereportthecaseofanasymptomaticsuspectedcarotidbodytumourfoundduring surveillance screening in a 72-year-old female who is a known carrier of a germline SDHA pathogenic variant. To our knowledge,thisisthefirstscreenthatdetectedPPGLfoundinapreviouslyidentifiedSDHA pathogenic variant carrier, duringsurveillanceimaging.Thisfindingsupportstheuseofcascadegenetictestingandsurveillancescreeninginall carriers of a pathogenic SDHA variant. Learning points: •• SDH mutations are important causes of PPGL disease. •• SDHA is much rarer compared to SDHB and SDHD mutations. •• Pathogenicity and penetrance are yet to be fully determined in cases of SDHA-related PPGL. •• Surveillance screening should be used for SDHA PPGL cases to identify recurrence, metastasis or metachronous disease. •• Surveillance screening for SDH-relateddiseaseshouldbeperformedinidentifiedcarriersofapathogenicSDHA variant.
    [Show full text]
  • Amplification of the Human Epidermal Growth Factor Receptor 2 (HER2) Gene Is Associated with a Microsatellite Stable Status in Chinese Gastric Cancer Patients
    387 Original Article Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients He Huang1#, Zhengkun Wang2#, Yi Li2, Qun Zhao3, Zhaojian Niu2 1Department of Gastrointestinal Surgery, The First Hospital of Shanxi Medical University, Shanxi, China; 2Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China; 3Department of Gastrosurgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China Contributions: I) Conception and design: Z Niu, Q Zhao, H Huang; (II) Administrative support: Z Niu, H Huang, Z Wang; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: Z Wang, Q Zhao; (V) Data analysis and interpretation: Z Niu, H Huang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Zhaojian Niu. Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Shinan District, Qingdao 260003, China. Email: [email protected]; Qun Zhao. Department of Gastrosurgery, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang 050011, China. Email: [email protected]. Background: Gastric cancer (GC) is one of the most common cancers worldwide. However, little is known about the combination of HER2 amplification and microsatellite instability (MSI) status in GC. This study aimed to analyze the correlation of HER2 amplification with microsatellite instability (MSI) status, clinical characteristics, and the tumor mutational burden (TMB) of patients. Methods: A total of 192 gastric cancer (GC) patients were enrolled in this cohort. To analyze genomic alterations (GAs), deep sequencing was performed on 450 target cancer genes.
    [Show full text]
  • High Prevalence of Occult Paragangliomas in Asymptomatic Carriers of SDHD and SDHB Gene Mutations
    European Journal of Human Genetics (2013) 21, 469–470 & 2013 Macmillan Publishers Limited All rights reserved 1018-4813/13 www.nature.com/ejhg SHORT REPORT High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations Berdine L Heesterman*,1, Jean Pierre Bayley2, Carli M Tops3, Frederik J Hes3, Bernadette TJ van Brussel3, Eleonora PM Corssmit4, Jaap F Hamming5, Andel GL van der Mey1 and Jeroen C Jansen1 Hereditary paraganglioma is a benign tumor syndrome with an age-dependent penetrance. Carriers of germline mutations in the SDHB or SDHD genes may develop parasympathetic paragangliomas in the head and neck region or sympathetic catecholamine-secreting abdominal and thoracic paragangliomas (pheochromocytomas). In this study, we aimed to establish paraganglioma risk in 101 asymptomatic germline mutation carriers and evaluate the results of our surveillance regimen. Asymptomatic carriers of an SDHD or SDHB mutation were included once disease status was established by MRI diagnosis. Clinical surveillance revealed a head and neck paraganglioma in 28 of the 47 (59.6%) asymptomatic SDHD mutation carriers. Risk of tumor development was significantly lower in SDHB mutation carriers: 2/17 (11.8%, P ¼ 0.001). Sympathetic paragangliomas were encountered in two SDHD mutation carriers and in one SDHB mutation carrier. In conclusion, asymptomatic carriers of an SDHD mutation are at a high risk for occult parasympathetic paraganglioma. SDHB carrier risk is considerably lower, consistent with lower penetrance of SDHB
    [Show full text]
  • SDHA Mutations in Adult and Pediatric Wild-Type Gastrointestinal Stromal
    Modern Pathology (2013) 26, 456–463 456 & 2013 USCAP, Inc All rights reserved 0893-3952/13 $32.00 SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors Lindsey Oudijk1,5 , Jose´ Gaal1,5, Esther Korpershoek1,5, Francien H van Nederveen1, Lorna Kelly2, Gaia Schiavon3, Jaap Verweij3, Ron HJ Mathijssen3, Michael A den Bakker1, Rogier A Oldenburg4, Rosa LE van Loon4, Maureen J O’Sullivan2, Ronald R de Krijger1 and Winand NM Dinjens1 1Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Josephine Nefkens Institute, Rotterdam, The Netherlands; 2Department of Pathology, Our Lady’s Children’s Hospital, Dublin, Ireland; 3Department of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands and 4Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands Most gastrointestinal stromal tumors (GISTs) harbor oncogenic mutations in KIT or platelet-derived growth factor receptor-a. However, a small subset of GISTs lacks such mutations and is termed ‘wild-type GISTs’. Germline mutation in any of the subunits of succinate dehydrogenase (SDH) predisposes individuals to hereditary paragangliomas and pheochromocytomas. However, germline mutations of the genes encoding SDH subunits A, B, C or D (SDHA, SDHB, SDHC or SDHD; collectively SDHx) are also identified in GISTs. SDHA and SDHB immunohistochemistry are reliable techniques to identify pheochromocytomas and paragangliomas with mutations in SDHA, SDHB, SDHC and SDHD. In this study, we investigated if SDHA immunohistochemistry could also identify SDHA-mutated GISTs. Twenty-four adult wild-type GISTs and nine pediatric/adolescent wild-type GISTs were analyzed with SDHB, and where this was negative, then with SDHA immunohistochemistry.
    [Show full text]
  • Genetic Testing for Hereditary Cancer Susceptibility
    Clinical Appropriateness Guidelines Genetic Testing for Hereditary Cancer Susceptibility EFFECTIVE FEBRUARY 2, 2020 Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2070-0319 Table of Contents Scope ................................................................................................................................................................ 3 Genetic Counseling Requirement ................................................................................................................... 3 Appropriate Use Criteria .................................................................................................................................. 3 Multi-Gene Panel Testing .................................................................................................................... 4 Germline Testing Following Identification of a Somatic Mutation .................................................... 4 ® ® * National Comprehensive Cancer Network (NCCN ) Criteria ......................................................... 5 CHEK2 ................................................................................................................................................... 5 Hereditary Paraganglioma-Pheochromocytoma Syndrome .............................................................. 6 Prostate Cancer.................................................................................................................................... 6 PALB2 ..................................................................................................................................................
    [Show full text]
  • Is CHEK2 a Moderate-Risk Breast Cancer Gene Or the Younger Sister Of
    BMJ Case Rep: first published as 10.1136/bcr-2020-236435 on 7 September 2020. Downloaded from Reminder of important clinical lesson Case report Is CHEK2 a moderate- risk breast cancer gene or the younger sister of Li- Fraumeni? Dilanka L De Silva ,1,2 Ingrid Winship3,4 1Department of Genetics, Royal SUMMARY (OR 3.3; 95% CI 2.3–4.7).8 CHEK2 in linked Melbourne Hospital, Parkville, The CHEK2 gene is mostly considered as a moderate with multiple cancers including prostate cancer: Victoria, Australia 1100delC mutation (OR 3.29; 95% CI 1.85–5.85; 2 breast cancer gene with the result that many clinicians Department of Genetics, Peter have a narrow focus. We present the 10- year journey of p=0.00) and I157T missense mutation (OR 1.80; MacCallum Cancer Institute, 95% CI 1.51–2.14; p=0.00).9 The age-adjusted and Melbourne, Victoria, Australia a man who had five different cancers and had iterative 3 sex- adjusted HRs were 5.76 (95% CI 2.12–15.6) Department of Clinical genetic testing including for Li-F raumeni syndrome, Genetics, The Royal Melbourne eventually to discover a pathogenic variant in the CHEK2 for stomach cancer, 3.61 (95% CI 1.33–9.79) for Hospital, Melbourne, Victoria, gene, possibly explaining his numerous cancers. This kidney cancer and 3.45 (95% CI 1.09–10.9) for 10 Australia diagnosis offered him closure which he had desperately sarcoma, and in a meta- analysis of a total of six 4Department of Medicine, sought for well over a decade.
    [Show full text]